Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2021-03-24 Director's Dealing
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of an individual (Sung Lee), their position (Member of the managing body), and records an 'Acquisition' of shares (American Depositary Shares) on a specific date (2021-03-23). This content directly matches the definition for Director's Dealing reports.
2021-03-24 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction by a 'person discharging managerial responsibilities' (Wendy Johnson, Member of the administrative or supervisory body). Section 4 details the nature of the transaction ('Acquisition'), the financial instrument (ADS), price, volume, and date. This content directly corresponds to the definition of Director's Dealing reports.
2021-03-23 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'DGAP-DD: MorphoSys AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities...'. This content directly matches the definition for Director's Dealing, which corresponds to the filing code DIRS. The document details the name of the person (Krisja Vermeylen), their position, the nature of the transaction (Acquisition), the price, volume, and date of the transaction involving company shares.
2021-03-22 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction (Acquisition) involving a 'person closely associated' with a director (Dr. Marc Cluzel) of MorphoSys AG. The structure, including sections like 'Details of the person discharging managerial responsibilities' and 'Details of the transaction(s)', is characteristic of insider trading or director dealing disclosures, which corresponds directly to the 'Director's Dealing' definition.
2021-03-19 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It details the name of an individual (Michael Brosnan), their position (Member of the administrative or supervisory body), and the nature of the transaction (Acquisition of American Depositary Shares). This content directly matches the definition for Director's Dealing reports.
2021-03-19 English
MorphoSys AG Presents Results for Full Year 2020
Earnings Release Classification · 1% confidence The document is titled "MorphoSys AG Presents Results for Full Year 2020" and explicitly states it reports "results for the year ended December 31, 2020". It contains detailed financial highlights, a full financial review for the year (IFRS), and an operational outlook for 2021. The presence of comprehensive annual financial data, including revenues, EBIT, net profit, and EPS for the full year, strongly indicates this is the company's primary annual financial disclosure. Although it is presented as a news release (DGAP-News), the content is the substance of the annual results report, not just a brief announcement of its release. Since the content is comprehensive and covers the full fiscal year, it aligns best with the Annual Report category (10-K), even if the specific filing format might be a German equivalent or a press release summarizing the 10-K data. Given the options, 10-K is the closest fit for a full-year financial performance report. It is not an Earnings Release (ER) because ERs are typically quarterly and focus only on highlights, whereas this covers the full year comprehensively. It is also not an RPA because the document contains the results themselves, not just an announcement that the results are available. FY 2020
2021-03-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.